What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Inmarsat Plc And UBM Plc

GlaxoSmithKline plc (LON:GSK), Inmarsat Plc (LON:ISAT) and UBM Plc (LON:UBM) are among the top holdings of Merchants Trust plc (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merchants Trust (LSE: MRCH) has delivered 32 consecutive years of dividend increases, and carries a trailing yield of 5.1% at a current share price of 463p.

Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

The trust holds many high-yield ‘usual suspects’, including Royal Dutch Shell, HSBC and current heavyweight top-yielder GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

But Merchants also has a couple of interesting mid-caps within its top 10 holdings: namely, mobile satellite communications firm Inmarsat (LSE: ISAT) and media group UBM (LSE: UBM).

GlaxoSmithKline

GSK has said shareholders can expect a total dividend of 80p for 2014, and the same payout for 2015 — giving a juicy annual yield of 5.7% at a current share price of 1,410p.

Some analysts have questioned whether GSK can afford to maintain the dividend during a phase of weaker sales, but chief executive Andrew Witty said recently: “I don’t think people should be concerned about that”.

In addition to the 80p dividend, shareholders can expect a £4bn capital return (82p a share) during 2015. The payment will be funded from net cash the company will receive as a result of a deal with Swiss group Novartis (expected to complete in the first half of the year) to swap some assets and create a consumer healthcare joint venture.

Inmarsat

Inmarsat was set up in 1979 by the International Maritime Organization to enable ships to stay in constant touch with shore or to call for help in an emergency. The company was floated on the stock market in 2005, and its operations now extend across air, land and sea.

At a current share price of 809p, Inmarsat has a market value of £3.5bn and sits just outside the FTSE 100. Annual dividend growth is running at 5% and analyst forecasts for 2015 give an above-market-average yield of 4%.

Earnings forecasts don’t fully cover the projected dividend (around $40m short), but at the last reckoning Inmarsat had cash on the balance sheet of $138m and available but undrawn borrowing facilities of $891m. Furthermore, management is “very confident of the medium-term growth opportunities for the company”.

UBM

Media group UBM operates internationally in three main business segments: Events, Marketing Services and PR Newswire. The company has a market value of £2.1bn at a current share price of 473p, and offers a 4.8% yield based on 2015 dividend forecasts.

During 2014, with the aid of a rights issue, UBM made a substantial acquisition in the shape of US trade show firm Advanstar. The deal makes UBM the biggest events organiser in America. Management says it also has “the opportunity to establish UBM firmly as the leading B2B events business globally”.

At the same time, the Board committed to continuing its progressive dividend policy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and UBM. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »